Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination

Published:2020-02-18 Issue:6 Volume:147 Page:1509-1518
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

De Guillebon Eleonore¹,Dardenne Antoine²,Saldmann Antonin³⁴,Séguier Sylvie³⁵,Tran Thi³,Paolini Lea³,Lebbe Celeste⁶⁷,Tartour Eric³⁴⁸^ORCID

Affiliation:

1. Department of Medical OncologyInstitut Curie Paris France

2. Department of Gastro‐enterology and Gastro‐intestinal OncologyHopital Européen Georges Pompidou, APHP Paris France

3. Université de Paris, PARCC, INSERM Paris France

4. Department of Immunology, AP‐HPHopital Européen Georges Pompidou Paris France

5. Faculté de Chirurgie DentaireHôpital Louis Mourier Montrouge France

6. Department of DermatologySaint‐Louis University Hospital Paris France

7. Université de Paris, INSERM U976 Paris France

8. Equipe Labellisée Ligue Contre le Cancer Paris France

Funder

Fondation ARC pour la Recherche sur le Cancer

Institut National Du Cancer

Ligue Contre le Cancer

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32889

Reference158 articles.

1. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation

2. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

3. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

4. Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)

5. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MMP-2/GSH-responsive nanobomb for tumor chemo-immunotherapy with hierarchical delivery and TAMs re-education by regulating hbegf-activated ERK/MAPK signal pathway;Chemical Engineering Journal;2024-07

2. Shifting cold to hot tumors by nanoparticle-loaded drugs and products;Clinical and Translational Oncology;2024-06-26

3. Anticancer Therapy with Proteolysis-targeting Chimeras [PROTACs] Targeting Towards the Tumor-microenvironment: Development, Current State and Prospects;Current Cancer Therapy Reviews;2024-05-14

4. Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials;Journal for ImmunoTherapy of Cancer;2024-04

5. Design of a single-center, phase II trial to explore the efficacy and safety of ‘R-ISV-RO’ treatment in advanced tumors;Future Oncology;2024-03-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3